KR880005270A - 단백질c의 발현 - Google Patents

단백질c의 발현 Download PDF

Info

Publication number
KR880005270A
KR880005270A KR870011997A KR870011997A KR880005270A KR 880005270 A KR880005270 A KR 880005270A KR 870011997 A KR870011997 A KR 870011997A KR 870011997 A KR870011997 A KR 870011997A KR 880005270 A KR880005270 A KR 880005270A
Authority
KR
South Korea
Prior art keywords
protein
human
dna sequence
arg
biological activity
Prior art date
Application number
KR870011997A
Other languages
English (en)
Other versions
KR970002166B1 (ko
Inventor
씨. 포스터 도날드
제이. 머레이 마크
엘. 버크너 캐틀린
Original Assignee
원본미기재
자이모 제네틱스. 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 자이모 제네틱스. 인코포레이티드 filed Critical 원본미기재
Publication of KR880005270A publication Critical patent/KR880005270A/ko
Application granted granted Critical
Publication of KR970002166B1 publication Critical patent/KR970002166B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

단백질C의 발현
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 PHC λ 6L 중의 단백질 C cDNA의 부분적인 제한지도이다.
제2도는 완전한 단백질 C cDNA의 뉴클레오티드 서열 및 단백질 C의 추측된아미노산 서열을 설명한 것이다.
제3도는 인체 단백질 C를 코드화하는 게놈 DNA의 제한효소지도이다.

Claims (15)

  1. 사람의 단백질 C 또는 사람의 활성화된 단백질 C 와 거의 동일한 생물학적 활성을 갖는 단백질을 코드화하고, 또한 고분자량쇄와 저분자량쇄 사이의 절단위치에 존재하는 아미노상 서열 (R1)n-R2-R3-R4(여기에서, R1, R2, R3및 R4은 Lys또는 Arg 이고 : n은 0, 1, 2 또는 3이다)을 코드화하는 DNA서열.
  2. 제1항에 있어서, 고분자량쇄와 저분자량쇄 사이의 절단위치에 존재하는 언급한 아미노상 서열이 Arg-Arg-Lys-Arg인 DNA 서열.
  3. 사람의 단백질 C 또는 사람의 활성화된 단백질 C와 거의 동일한 생물학적 활성을 갖는 단백질을 코드화하고, 또한 인자 VII, 인자 IX, 인자 X 프로트롬빈 및 단백질 S중에서 선택되는 단백질의 프리-프로 펩타이드를 코드화 하는 DNA서열.
  4. 사람의 단백질 C 또는 사람의 활성화된 단백질 C 와 거의 동일한 생물학적 활성을 가지며, 또한 잔기 158이 Ala, Ser, Thr및 Gly중에서 선택되는 비산성 아미노산잔기로 치환된 단백질을 코드화하는 DNA 서열.
  5. 사람의 단백질 C 또는 사람의 활성화된 단백질 C와 거의 동일한 생물학적 활성을 가지며, 잔기 154가 Lys 또는 Arg 중에서 선택되는 염기성 아미노산 잔기로 치환된 단백질을 코드화하는 DNA서열.
  6. 사람의 단백질 C 또는 사람의 활성화된 단백질 C와 거의 동일한 생물학적 활성을 가지며, 잔기 156내지 157의 Lys-Arg이 Lys-Arg 또는Arg- Arg 로 치환된 단백질을 코드화하는 DNA 서열.
  7. 제1항 내지 6항중 어느 한 항에 따른 DNA서열(여기에서, DNA서열은 폴리아데닐화 신호의 상부에 존재한다)의 상부에 존재하면서 DNA 서열의 전사를 유도하는 프로모터를 함유하는, 포유동물 숙주 세포 DNA에 도입시킬수 있는 발현벡터.
  8. 제7항에 따른 발현벡터로 형질전환된 포유동물 세포.
  9. 제8항에 있어서, 상기의 세포가, COS, BHK,쥐의 HepI, 쥐의 HepⅡ, TCMK,사람의 폐, 사람의 간종양, Hep G2, 마우스의 간, DUKX 및 293 세포중에서 선택되는 세포.
  10. 포유동물 숙주세포에 제7항에 따른 발현벡터를 도입시킨 다음, 적절한 배지에서 성장시키고, 이어서 상기의 발현벡터에 의해 코드화 되고 상기의 포유동물 숙주세포에 의해 생성된 단백질 생성물을 분리시킴을 특징으로 하여, 활성화된 경우에 사람의 활성화된 단백질 C와 거의 동일한 구조 및/ 또는 생물학적 활성을 갖는 단백질을 제조하는 방법.
  11. 제10항에 있어서, 상기의 세포가 COS, BHK, 쥐의 HepI, 쥐의 HepⅡ, TCMK, 사람의 폐, 사람의 간종양, Hep G2, 마우스 간, DUKX 및 293 세포중에서 선택되는 방법.
  12. BHK숙주 세포 DNA에 도입시킬 수 있으며, 제1항, 제5항 또는 제6항중 어느 한 항에 따른 DNA 서열의 상부에 DNA서열의 전사를 유도하는 프로모터가 존재하고, 상기 DNA 서열의 하부에 폴리아데닐화 신호가 존재하는 발현벡터를 BHK 숙주 세포에 도입시긴 다음 : 적절한 배지에 성장시키고 : 이어서 상기의 DNA서열에 의해 코드화 되고 상기의 BHK 숙주세포에 의해 생성된 단백질 생성물을 분리시킴을 특징으로 하여, 활성화된 경우에 사람의 활성화된 단백질 C와 거의 동일한 구조 및/ 또는 생물학적 활성을 갖는 단백질을 제조하는 방법.
  13. 제10항 내지 제12항중 어느 한 항에 있어서, 숙주 세포에 상기의 발현벡터와 함께 선별표지를 더 도입시키는 방법.
  14. 제10항 내지 제12항중 어느 한 항에 있어서, 사람의 활성화된 단백질의 C와 거의 동일한 생물학적 활성을 갖는 단백질을 제조하기 위하여 단백질 생성물을 활성화 시키는 단계를 더 포함하는 방법
  15. 제14항에 있어서, 활성화 단계가 단백질 생성물을 α-트룸빈, 트립신 및 독성 활성제중에서 선택되는 푸로테아제로 절단시키을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870011997A 1986-10-29 1987-10-29 단백질 c를 암호화하는 dna 서열, 이를 함유하는 재조합 벡터, 재조합 벡터를 함유하는 포유동물 세포 및 단백질 c를 제조하는 방법 KR970002166B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US06/924,462 US4959318A (en) 1985-06-27 1986-10-29 Expression of protein C
US06/924462 1986-10-29
US924462 1997-08-23

Publications (2)

Publication Number Publication Date
KR880005270A true KR880005270A (ko) 1988-06-28
KR970002166B1 KR970002166B1 (ko) 1997-02-24

Family

ID=25450229

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870011997A KR970002166B1 (ko) 1986-10-29 1987-10-29 단백질 c를 암호화하는 dna 서열, 이를 함유하는 재조합 벡터, 재조합 벡터를 함유하는 포유동물 세포 및 단백질 c를 제조하는 방법

Country Status (9)

Country Link
US (1) US4959318A (ko)
EP (1) EP0266190B1 (ko)
JP (2) JP2561677B2 (ko)
KR (1) KR970002166B1 (ko)
AT (1) ATE90966T1 (ko)
CA (1) CA1340263C (ko)
DE (1) DE3786321T2 (ko)
DK (1) DK175183B1 (ko)
NO (1) NO173741C (ko)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) * 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
JPH01502080A (ja) * 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
EP0296413A2 (en) * 1987-06-12 1988-12-28 Hoechst Japan Limited Hybrid protein C and method for its preparation
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2728240B2 (ja) * 1988-07-26 1998-03-18 ヘキスト薬品工業株式会社 ヒトプロテインｃ変異体及びその製造方法
US5571691A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5766939A (en) * 1989-05-05 1998-06-16 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
IL94183A (en) 1989-05-05 2003-09-17 Baylor College Medicine cDNA SEQUENCE CODING FOR HUMAN LACTOFERRIN PROTEIN OR PORTION THEREOF AND LACTOFERRIN PROTEIN PRODUCED FROM SAID SEQUENCE
US6100054A (en) * 1989-05-05 2000-08-08 Baylor College Of Medicine Production for recombinant lactoferrin and lactoferrin polypeptides using DNA sequences in various organisms
US5849881A (en) * 1989-05-05 1998-12-15 Baylor College Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using cDNA sequences in various organisms
ATE97958T1 (de) * 1989-08-11 1993-12-15 Zymogenetics Inc Zellenzuchtverfahren fuer die produktion von aktiviertem protein-c.
JP2774156B2 (ja) * 1989-09-05 1998-07-09 帝人株式会社 ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
JP2774163B2 (ja) * 1989-11-14 1998-07-09 帝人株式会社 ヒトプロテインｃ様活性を有する蛋白
JP3153236B2 (ja) * 1989-12-22 2001-04-03 ザイモジェネティクス，インコーポレイティド 端が切り取られた軽鎖を有する組換えプロテインｃ
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
ATE163048T1 (de) * 1989-12-29 1998-02-15 Zymogenetics Inc Hybrides protein c
WO1991011514A1 (en) * 1990-01-29 1991-08-08 Zymogenetics, Inc. Anticoagulant proteins
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
AU1337092A (en) * 1991-01-29 1992-08-27 Brigham And Women's Hospital A cdna encoding the type i iodothyronine 5' deiodinase
US5272078A (en) * 1991-01-29 1993-12-21 Brigham And Women's Hospital CDNA encoding the type I iodothyronine 5'deiodinase
EP0530365A1 (en) * 1991-01-29 1993-03-10 Teijin Limited Human protein c expression vector
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5997864A (en) * 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5876985A (en) * 1991-04-25 1999-03-02 Board Of Regents, The University Of Texas System Methods and compositions for the preparation of recombinant Trichomonas vaginalis proteins and peptides
AT402263B (de) * 1991-06-20 1997-03-25 Immuno Ag Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
DE4229933A1 (de) * 1992-09-08 1994-03-10 Max Planck Gesellschaft Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5905185A (en) * 1995-11-30 1999-05-18 Ppl Therapeutics Protein C production in non-human transgenic mammals
US6111081A (en) * 1996-05-31 2000-08-29 Baylor College Of Medicine Lactoferrin variants and uses thereof
DE69735597T2 (de) * 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c
US6165771A (en) * 1997-06-10 2000-12-26 Smithkline Beecham, P.L.C. Compounds
US6924359B1 (en) 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
MXPA03003388A (es) * 2000-10-18 2005-03-07 Maxygen Aps Moleculas de proteina c o similares a las de proteina c activadas.
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2004113385A1 (en) * 2003-06-20 2004-12-29 Maxygen Holdings Ltd. Protein c propeptide variants
US20080305100A1 (en) * 2004-07-23 2008-12-11 Zlokovic Berislav V Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
KR102068010B1 (ko) 2012-07-04 2020-01-20 제트제트 바이오테크 엘엘씨 염증성 피부 질환의 치료
CN106573040B (zh) 2014-04-16 2021-07-06 Zz生物技术有限责任公司 治疗异常皮肤瘢痕形成

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
GB8327860D0 (en) * 1983-10-18 1983-11-16 Fujisawa Pharmaceutical Co Monoclonal antiprotein c antibody
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GR861037B (en) * 1985-04-22 1986-07-16 Genentech Inc Novel human tissue plasminogen activator mutants
ATE74164T1 (de) * 1985-04-22 1992-04-15 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
EP0215548B2 (en) * 1985-06-27 1998-01-07 Zymogenetics, Inc. Expression of protein C

Also Published As

Publication number Publication date
DK567087D0 (da) 1987-10-29
EP0266190A2 (en) 1988-05-04
NO173741B (no) 1993-10-18
EP0266190A3 (en) 1989-10-25
JP2922461B2 (ja) 1999-07-26
DK175183B1 (da) 2004-06-28
NO173741C (no) 1994-01-26
CA1340263C (en) 1998-12-15
KR970002166B1 (ko) 1997-02-24
NO874495D0 (no) 1987-10-28
JPS6485084A (en) 1989-03-30
DE3786321T2 (de) 1993-09-30
JP2561677B2 (ja) 1996-12-11
EP0266190B1 (en) 1993-06-23
JPH08252094A (ja) 1996-10-01
NO874495L (no) 1988-05-02
US4959318A (en) 1990-09-25
DE3786321D1 (de) 1993-07-29
ATE90966T1 (de) 1993-07-15
DK567087A (da) 1988-04-30

Similar Documents

Publication Publication Date Title
KR880005270A (ko) 단백질c의 발현
Rottier et al. Predicted membrane topology of the coronavirus protein E1
Williamson et al. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP)
KR920701451A (ko) 인체혈청알부민의 n-말단 단편을 함유하는 융합 단백질
Atherton et al. Peptide synthesis. Part 7. Solid-phase synthesis of conotoxin G1
KR850007275A (ko) 기능성 인체인자 ⅷ의 제조방법
EP0150126A3 (en) The synthesis of protein with an identification peptide
ATE173018T1 (de) Herstellung von fusionsproteinen
Chang Controlling the speed of hirudin folding
DE3855084D1 (de) Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist
Hubbard et al. Vitamin K-dependent carboxylation: in vitro modification of synthetic peptides containing the γ-carboxylation recognition site
DE69310734T2 (de) Peptid für die stimulierung von für hepatitis c virus spesifischen cytotoischen t lymphozyten
JPS6420095A (en) Polypeptide having anti-blood coagulating action
KR910006483A (ko) 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
KR930021783A (ko) 진균 프로테아제
Guy et al. The Structure of the Bovine Pancreatic Secretory Trypsin Inhibitor—Kazal's Inhibitor: III. DETERMINATION OF THE DISULFIDE BONDS AND PROTEOLYSIS BY THERMOLYSIN
LeBoeuf et al. Human apolipoprotein B: partial amino acid sequence
DE69027466T2 (de) Achromobacter-Protease-I-Gen sowie Genprodukt
čeřovský et al. Enzymatic semisynthesis of dicarba analogs of calcitonin
KR900702017A (ko) 혼성 단백질(bybrid proteins)
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
Olson et al. Limited proteolysis as a probe of the conformation and nucleic acid binding regions of nucleolin
KR910700351A (ko) C-말단 α- 아미드화된 펩타이드의 생산방법
Lynn et al. Homologies of the N-terminal sequences of asclepains and papain
Teruya et al. Total synthesis of [L40I, C90A, C109A]-human T-cell leukemia virus type 1 protease

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20060217

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee